AR116866A1 - Enzimas de degradación de cistina / cisteína de primates modificadas por ingeniería genética - Google Patents

Enzimas de degradación de cistina / cisteína de primates modificadas por ingeniería genética

Info

Publication number
AR116866A1
AR116866A1 ARP190103101A ARP190103101A AR116866A1 AR 116866 A1 AR116866 A1 AR 116866A1 AR P190103101 A ARP190103101 A AR P190103101A AR P190103101 A ARP190103101 A AR P190103101A AR 116866 A1 AR116866 A1 AR 116866A1
Authority
AR
Argentina
Prior art keywords
genetic engineering
cystine
modified
degradation enzymes
enzymes
Prior art date
Application number
ARP190103101A
Other languages
English (en)
Inventor
Christos Karamitros
Wei Lu
- Stone Everett Cheng
Original Assignee
Univ Texas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Texas filed Critical Univ Texas
Publication of AR116866A1 publication Critical patent/AR116866A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y404/00—Carbon-sulfur lyases (4.4)
    • C12Y404/01—Carbon-sulfur lyases (4.4.1)
    • C12Y404/01001—Cystathionine gamma-lyase (4.4.1.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
    • A61B17/22—Implements for squeezing-off ulcers or the like on the inside of inner organs of the body; Implements for scraping-out cavities of body organs, e.g. bones; Calculus removers; Calculus smashing apparatus; Apparatus for removing obstructions in blood vessels, not otherwise provided for
    • A61B17/225—Implements for squeezing-off ulcers or the like on the inside of inner organs of the body; Implements for scraping-out cavities of body organs, e.g. bones; Calculus removers; Calculus smashing apparatus; Apparatus for removing obstructions in blood vessels, not otherwise provided for for extracorporeal shock wave lithotripsy [ESWL], e.g. by using ultrasonic waves
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/51—Lyases (4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/52—Genes encoding for enzymes or proenzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/88—Lyases (4.)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Surgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Plant Pathology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Vascular Medicine (AREA)
  • Medical Informatics (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

Se describen métodos y composiciones relacionadas con la modificación por ingeniería genética de una proteína con L-cist(e)ína que degrada la activad enzimática. Por ejemplo, se divulgan cistationina-g-liasas modificadas que comprenden una o más sustituciones de aminoácidos y que pueden degradar L-cist(e)ína. Además, se proporcionan composiciones y métodos para el tratamiento de la cistinuria usando las enzimas modificadas divulgadas o los ácidos nucleicos que codifican dichas enzimas.
ARP190103101A 2018-10-26 2019-10-25 Enzimas de degradación de cistina / cisteína de primates modificadas por ingeniería genética AR116866A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201862751197P 2018-10-26 2018-10-26

Publications (1)

Publication Number Publication Date
AR116866A1 true AR116866A1 (es) 2021-06-23

Family

ID=70331739

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP190103101A AR116866A1 (es) 2018-10-26 2019-10-25 Enzimas de degradación de cistina / cisteína de primates modificadas por ingeniería genética

Country Status (15)

Country Link
US (1) US20210380962A1 (es)
EP (1) EP3870081A4 (es)
JP (1) JP2022505689A (es)
KR (1) KR20210084539A (es)
CN (1) CN113260324A (es)
AR (1) AR116866A1 (es)
AU (1) AU2019363606A1 (es)
BR (1) BR112021007687A2 (es)
CA (1) CA3117046A1 (es)
CO (1) CO2021006432A2 (es)
IL (1) IL282626A (es)
MX (1) MX2021004754A (es)
SG (1) SG11202104205XA (es)
TW (1) TW202029967A (es)
WO (1) WO2020086937A1 (es)

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060275279A1 (en) * 2005-06-06 2006-12-07 Rozzell J D Methods for dissolving cystine stones and reducing cystine in urine
CN102791856B (zh) * 2010-02-04 2016-12-07 艾莫瑟有限公司 用甲硫氨酸-γ-裂合酶加工的酶和其药理学制备物
ES2745287T3 (es) * 2013-08-29 2020-02-28 Univ Texas Enzimas degradadoras de cistina/cisteína de primate genomanipuladas como agentes antineogénicos
WO2015031726A2 (en) * 2013-08-29 2015-03-05 Board Of Regents, The University Of Texas System Engineered primate l-methioninase for therapeutic purposes
EP3187190A1 (en) * 2015-12-31 2017-07-05 Erytech Pharma Method of treating a mammal, including human, against cancer using methionine and asparagine depletion
IL270503B1 (en) * 2017-05-12 2024-06-01 Univ Texas Depletion of homocysteine by human enzymes for the treatment of patients with hyperhomocysteinemia and homocystinuria
US10865403B2 (en) * 2017-05-12 2020-12-15 Board Of Regents, The University Of Texas System Engineered primate cystine/cysteine degrading enzymes for therapeutic uses

Also Published As

Publication number Publication date
AU2019363606A1 (en) 2021-05-20
US20210380962A1 (en) 2021-12-09
EP3870081A1 (en) 2021-09-01
MX2021004754A (es) 2021-06-08
IL282626A (en) 2021-06-30
CO2021006432A2 (es) 2021-06-10
WO2020086937A1 (en) 2020-04-30
JP2022505689A (ja) 2022-01-14
CN113260324A (zh) 2021-08-13
BR112021007687A2 (pt) 2021-08-10
EP3870081A4 (en) 2023-01-18
SG11202104205XA (en) 2021-05-28
KR20210084539A (ko) 2021-07-07
TW202029967A (zh) 2020-08-16
CA3117046A1 (en) 2020-04-30

Similar Documents

Publication Publication Date Title
NI201800121A (es) Proteínas de fusión gdf15 y usos de estas
BR112021023457A2 (pt) Composto, uso do composto, composição, e, métodos para preparar a composição e um composto
CO2019009258A2 (es) Administración rápida y controlada de composiciones con efectos séquito restaurados
CL2019003248A1 (es) Disminución de homocisteína mediada por enzimas humanas para el tratamiento de pacientes con hiperhomocisteinemia y homocistinuria.
EA201890137A1 (ru) Среда для культивирования клеток с добавлением таурина и способы применения
PE20180743A1 (es) Metodo para produccion de l-aminoacido
BRPI0820114A8 (pt) Método de aumentar a sensibilidade de uma fitase derivada de escherichia coli a uma pepsina
BR112013032396A2 (pt) formulações estáveis de aplicações relacionadas à enzima de degradação de ácido hialurônico
BR112022004699A2 (pt) Vs-6063 em combinação com ch5126766 para o tratamento de câncer
ATE512228T1 (de) Induzierbare expressionssysteme
BR112019000693A2 (pt) composições de muc1- car e métodos para uso
WO2015031726A3 (en) Engineered primate l-methioninase for therapeutic purposes
WO2020030984A3 (en) Compositions and methods for genome engineering with cas12a proteins
BR112015021960A2 (pt) Células hospedeiras e métodos de uso
MX2019000235A (es) Eliminacion de la cistina mediada por enzimas humanas.
PE20170955A1 (es) Nuevas proteinas inhibidoras de insectos
EA200800253A1 (ru) Бессывороточная культуральная среда для получения рекомбинантных гонадотропинов
AR103794A1 (es) Producción de alquenos
CO2020013050A2 (es) Enzimas quinureninasa humanas y sus usos
CL2023000554A1 (es) Proteínas diseñadas y métodos de uso de las mismas.
CO2021007006A2 (es) Moduladores de la expresión de irf5
DE602007001519D1 (de) Zusammensetzung mit mehreren botulinumtoxinen
AR100607A1 (es) Un método para la modificación de una lipasa
BR112018072968A2 (pt) peptídeos monolipidados resistentes às proteases
BR112018077510A2 (pt) variantes de lipase e composições que compreendem tensoativo e variante de lipase